2Seventy Bio

2Seventy Bio Supply Chain

Delisted

Supply Chain of 2Seventy Bio (TSVT) as of Nov 5, 2026.

Supply Chain

-

Last updated:

Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.

2Seventy Bio Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#NameTrend
1
Biogen
Supplier·Customer·Biotechnology·US
0.79
0.81
0.77
0.84
—
—
2
Roivant Sciences
Supplier·Customer·Pharmaceuticals·GB
0.65
0.69
0.25
0.86
—
—
3
Regeneron Pharmaceuticals
Supplier·Customer·Biotechnology·US
0.58
0.29
0.74
-0.15
—
—
4
Bristol-Myers Squibb
Supplier·Customer·Pharmaceuticals·US
0.50
-0.25
0.10
-0.74
—
—
5
Alexandria Real Estate
Supplier·Equity Real Estate Investment Trusts (REITs)·US
0.36
0.87
0.77
0.82
—
—
6
Gritstone bio
Supplier·Customer·Biotechnology·US
0.07
0.88
0.45
0.92
—
—
7
Showa Denko
Supplier·Customer·Chemicals·JP
0.07
0.50
0.25
0.55
—
—
8
Inhibrx
Supplier·Customer·Biotechnology·US
-0.03
0.81
0.67
0.94
—
—
9
Novo Nordisk B
Supplier·Customer·DK
-0.52
0.63
0.20
-0.04
—
—
10
MediGene
Supplier·Customer·Biotechnology·DE
-0.62
0.46
0.61
0.07
—
—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2seventy Bio, Inc. generates revenue through its cell and gene therapy programs, including SC-DARIC33 for pediatric relapsed and refractory acute myeloid leukemia and bbT369 for B-cell non-Hodgkin lymphoma. The company collaborates with Bristol Myers Squibb to deliver Abecma for multiple myeloma patients in the U.S., leveraging its T cell engineering and lentiviral vector technologies. Its clinical and preclinical programs, such as bbT4015 targeting MUC16, form the core of its product pipeline. The company focuses on developing targeted cellular therapies for cancer patients, with Bristol Myers Squibb as a key partner in commercializing Abecma. 2seventy Bio, Inc. operates in the biopharmaceutical sector, targeting patients with specific cancer types through its advanced therapies. Its products are developed using proprietary T cell engineering and lentiviral vector delivery systems. The company's revenue streams include clinical trial partnerships and potential future commercial sales of its therapies. Bristol Myers Squibb supports the U.S. distribution of Abecma, a key product in its portfolio. 2Seventy Bio is one of the most popular companies on Eulerpool.

All Key Metrics — 2Seventy Bio